« Recent News

Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers

AUSTIN, Texas, Sept. 3, 2015 — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Herbert Fritsche, Ph.D., the Lab Director of Vermillion’s wholly owned subsidiary, ASPiRA LABS, is the recipient of the 2015 Abbott Award, given by the International Society of Oncology and Biomarkers (ISOBM) for outstanding contributions to the field of basic or clinical oncology. Dr. Fritsche will receive the award on October 5th in Zakopane, Poland. Prior to ASPiRA LABS, Dr. Fritsche was a professor of biochemistry and clinical chemistry section chief at the University of Texas M. D. Anderson Cancer Center. He received his Ph.D. in chemistry from Texas A&M University.

Valerie Palmieri, President and CEO of Vermillion, noted “We are so proud to be associated with a person of Dr. Fritsche’s caliber and deep experience. As the Lab Director for ASPiRA LABS, he has been instrumental in developing our lab and creating a customer experience which we believe delivers exceptionally high quality and service. The 2015 Abbott Award from ISOBM is well-deserved recognition from the diagnostic community for the high quality of work he has contributed in the field of oncology and cancer biomarkers.”

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company’s lead diagnostic, OVA1, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

ASPiRA Labs is a diagnostic services laboratory founded by Vermillion, Inc., a leader in women’s health diagnostics. The laboratory’s goal is to provide high quality, innovative testing and bio-analytics for women to help address unmet women’s health needs. ASPiRA Labs’ specialized services are grounded in evidence-based medicine, while providing access to novel biomarker diagnostic tools designed to help health care professionals offer the most precise diagnoses and treatment guidance for their patients.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
[email protected]